Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alberto Martini

Showing results (511-520 of 549) with videos related to

Pageof 55
Sort By:
Arthritis Care & Research|March 2, 2010
Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patientsAngelo Ravelli, Lucia Trail, Cristina Ferrari, et al.
European Urology Open Science|July 11, 2022
The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk CalculatorSneha Parekh, Parita Ratnani, Ugo Falagario, et al.
The New England Journal of Medicine|December 21, 2012
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritisNicolino Ruperto, Hermine I Brunner, Pierre Quartier, et al.
Rheumatology (Oxford, England)|October 5, 2017
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspectsLisa G Rider, Nicolino Ruperto, Angela Pistorio, et al.
Annals of the Rheumatic Diseases|August 2, 2012
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritisGeorge K Bertsias, Maria Tektonidou, Zahir Amoura, et al.
Lancet (London, England)|November 12, 2021
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trialNicolino Ruperto, Hermine I Brunner, Olga Synoverska, et al.
Rheumatology (Oxford, England)|January 25, 2021
Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritisNicolino Ruperto, Hermine I Brunner, César Pacheco-Tena, et al.
Lancet (London, England)|December 10, 2015
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trialNicolino Ruperto, Angela Pistorio, Sheila Oliveira, et al.
Annals of the Rheumatic Diseases|May 17, 2017
Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trialHermine I Brunner, Nicolino Ruperto, Nikolay Tzaribachev, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 1, 2014
Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patientsFrancesca Minoia, Sergio Davì, AnnaCarin Horne, et al.
Pageof 55

Showing results (511-520 of 549) with videos related to

Sort By:
Pageof 55
Arthritis Care & Research|March 2, 2010
Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patientsAngelo Ravelli, Lucia Trail, Cristina Ferrari, et al.
European Urology Open Science|July 11, 2022
The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk CalculatorSneha Parekh, Parita Ratnani, Ugo Falagario, et al.
The New England Journal of Medicine|December 21, 2012
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritisNicolino Ruperto, Hermine I Brunner, Pierre Quartier, et al.
Rheumatology (Oxford, England)|October 5, 2017
2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspectsLisa G Rider, Nicolino Ruperto, Angela Pistorio, et al.
Annals of the Rheumatic Diseases|August 2, 2012
Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritisGeorge K Bertsias, Maria Tektonidou, Zahir Amoura, et al.
Lancet (London, England)|November 12, 2021
Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trialNicolino Ruperto, Hermine I Brunner, Olga Synoverska, et al.
Rheumatology (Oxford, England)|January 25, 2021
Open-label phase 3 study of intravenous golimumab in patients with polyarticular juvenile idiopathic arthritisNicolino Ruperto, Hermine I Brunner, César Pacheco-Tena, et al.
Lancet (London, England)|December 10, 2015
Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trialNicolino Ruperto, Angela Pistorio, Sheila Oliveira, et al.
Annals of the Rheumatic Diseases|May 17, 2017
Subcutaneous golimumab for children with active polyarticular-course juvenile idiopathic arthritis: results of a multicentre, double-blind, randomised-withdrawal trialHermine I Brunner, Nicolino Ruperto, Nikolay Tzaribachev, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|August 1, 2014
Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patientsFrancesca Minoia, Sergio Davì, AnnaCarin Horne, et al.
Pageof 55